Afferent Pharmaceuticals Receives $23,000,000 Series A Round

  • Feed Type
  • Date
    12/16/2009
  • Company Name
    Afferent Pharmaceuticals
  • Mailing Address
    29 Newbury Street Boston, MA 02116
  • Company Description
    Develops medicines to treat chronic pain. Afferent Pharmaceuticals is focused on developing first-in-class medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. Research shows that P2X3-containing receptors are highly specific to nerve fibers that transmit the sensations of pain and discomfort in response to inflammation or injury, particularly in chronic conditions. P2X3 antagonism represents a breakthrough and potentially transformative approach to treating chronic pain associated with conditions such as osteoarthritis, back pain, visceral pain and neuropathy.
  • Website
    http://www.afferentpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $23,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds from the financing will be used toaccelerate the development of P2X3 receptor targeted pain therapies.
  • M&A Terms
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    Pappas Ventures
  • Venture Investor
    Domain Associates
  • Venture Investor
    New Leaf Venture Partners

Trending on Xconomy